

Revcovi (elapegademase)
Effective 06/19/2019

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit (NLX)		
Specialty Limitations	N/A		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

FDA-Approved Indication

Treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients

Coverage Guidelines

Authorization may be granted for members who are currently receiving treatment with Revcovi, excluding when the product is obtained as samples or via manufacturer's patient assistance programs

OR

Authorization may be granted for treatment of ADA-SCID when the following criteria are met, and documentation has been provided:

1. Member has confirmed severe combined immunodeficiency disease (SCID) with a definitive diagnosis of adenosine deaminase deficiency as determined by one of the following:
 - a. Deficient ADA catalytic activity (<1% of normal) in hemolysates (in untransfused patients) or in extracts of other cells (e.g., blood mono nuclear cells, fibroblasts) **OR**
 - b. Detection of mutations in the ADA gene by molecular genetic testing **AND**
2. Member has a marked elevations of the metabolite dATP or total dAdo nucleotides in erythrocytes **AND**
3. Member is not a candidate for or has failed a bone marrow transplant
4. Baseline values for plasma ADA activity red blood cell deoxyadenosine triphosphate (dATP), trough deoxyadenosine nucleotide (dAXP) and/or lymphocyte counts have been obtained.

Continuation of Therapy

Reauthorization may be granted when then following criteria/conditions have been met:

1. Member continues to meet initial criteria

2. Documentation of disease stability and/or improvement as evidenced by one or more of the following:
3. Increase in plasma ADA activity (target trough level ≥ 15 mmol/hr/L)
4. Red blood cell dATP level decreased (target ≤ 0.005 to 0.015 mmol/L)
5. Improvement in immune function with decrease in frequency of infections
6. Improvement in red blood cell dAXP levels (target trough level ≤ 0.02 mmol/L)

Limitations

Approvals are granted for 12 months.

Appendix

Recommended Dosing

- For Adagen-naïve patients;
- Starting dose of Revcovi is 0.2mg/kg twice a week IM for minimum of 12 to 24 weeks
- Dose maybe gradually adjusted down to maintain trough ADA activity over 30 mmol/hr/L, trough dAXP level under 0.02 mmol/L and/or to maintain adequate immune function.
- For patients transitioning from Adagen to Revcovi:
- If a patient's weekly Adagen dose is unknown or is at or lower than 30U/Kg, recommended starting of Revcovi is 0.2mg/kg, IM once a week
- If a patient's weekly Adagen dose is above 30 U/kg, the equivalent Revcovi dose should be calculated as follows:

Revcovi dose in mg/kg = Adagen dose in U/kg \div 150

References

1. Revcovi [package insert]. Indianapolis, IN; Leadiant Biosciences; October 2018. Accessed January 2019
2. Hershfield, M. Adenosine Deaminase Deficiency. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1483/ (Accessed on September 1, 2017).
3. Gaspar HB, Aiuti A, Porta F, et al. How I treat ADA deficiency. *Blood*. 2009 October 22; 114(17): 3524–3532.
4. Adenosine Deaminase Deficiency-genetic and Rare Diseases Information Center. US Department of health and human services-NIH. Available at: <https://rarediseases.info.nih.gov/diseases/5748/adenosine-deaminase-deficiency>
5. Flinn AM, Gennery AR. Adenosine deaminase deficiency: a review. *Orphanet Journal of Rare Diseases* 2018. <https://doi.org/10.1186/s13023-018-0807-5>

Review History

06/19/19 – Reviewed.

